H.C. Wainwright analyst Matthew Caufield lowered the firm’s price target on Ocuphire Pharma to $20 from $26 and keeps a Buy rating on the shares. The analyst interprets the primary endpoint miss in the Phase 2 ZETA-1 trial for APX3330 as a setback, "albeit an opportunity to evaluate the future direction for the program."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OCUP:
- OCUP Tanks as Clinical Data Disappoints
- Ocuphire craters 31% after trial evaluating oral APX3330 fails to meet endpoint
- Ocuphire Pharma did not meet the primary endpoint in Oral APX3330 trial
- Ocuphire Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA
- Ocuphire Pharma enrolls first patient in VEGA-2 Phase 3 trial of Nyxol
